UFP Technologies has delivered earnings beats in all four consecutive recent quarters with an average surprise of 9.4%, reflecting improving execution in medical devices, though high short interest of 20% and elevated put/call ratio of 2.67 signal meaningful bearish positioning that must be worked through.
Thesis pillars
- Analyst Upside Versus Risk Reward→Stable
- Perfect Four Quarter Beat Streak→Stable
- Strong Momentum With Macd Signal↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
UFP Technologies, Inc. (UFPT) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Devices
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $237.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: top ten customers (68.8%); Weak growth.
UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient medical devices and components for minimally invasive surgery, infection prevention, wound care, and orthopedics. The company generates revenue by manufacturing... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $237.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: top ten customers (68.8%); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About UFP Technologies, Inc.
About UFP Technologies, Inc.
UFP Technologies operates nineteen ISO 13485-certified manufacturing sites, thirteen of them FDA-registered, producing single-use and single-patient medical devices for surgical, wound-care, and orthopedic applications. Two customers, Intuitive Surgical SARL and Stryker, accounted for approximately 24.3% and 21.5% of net sales in 2025, respectively, while the top ten customers together represented about 68.8% of net sales. The company also runs manufacturing operations in the Dominican Republic.
UFP Technologies earns revenue as a contract developer and manufacturer, converting foam, plastics, and other specialty materials into custom-engineered components through cutting, molding, thermoforming, and welding processes for medical device customers. The company sells principally through a direct sales force, with commercial leaders and engineers collaborating with customers to develop application-specific solutions across minimally invasive surgery, infection prevention, wound care, and orthopedic implants. Raw materials such as cross-linked foam, technical polyurethane foam, and thermoplastic urethane come from a limited number of suppliers, though the company describes its supplier relationships as good. Competition comes primarily from smaller independent regional manufacturers rather than large national converters, and some customers have brought manufacturing in-house or could do so, a dynamic the filing flags as a competitive risk. Research and development is described as an integral part of the company's ongoing cost structure rather than a standalone profit center.
Show full overview
UFP Technologies' customer base is concentrated enough that a single lost account could move results: Intuitive Surgical SARL and Stryker together represented about 45.8% of 2025 net sales, and one customer held 32.1% of gross accounts receivable at year-end. The company also disclosed a material information-technology security incident detected on February 14, 2026, in which data were exfiltrated from systems supporting billing and shipping-label functions, with the investigation into affected personal information still ongoing. Combined with reliance on a limited number of suppliers for cross-linked and technical polyurethane foam and TPU, and manufacturing operations near civil unrest in Haiti that could disrupt Dominican Republic facilities, the filing points to concentrated commercial and operational dependencies rather than commodity-style diversification.
See also: Healthcare · Medical Devices
From UFP Technologies, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — UFP Technologies, Inc.
Latest news
- NEWS UFP Technologies (UFPT) to Release Earnings on Tuesday - MarketBeat — MarketBeat neutral
- NEWS UFP Technologies (UFPT) tops Q1 earnings estimates - MSN — MSN positive
- NEWS Montrusco Bolton Investments Inc. Has $4.51 Million Stock Position in UFP Technologies, Inc. $UFPT - MarketBeat — MarketBeat neutral
- NEWS UFP Technologies (UFPT) Tops Q1 Earnings Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS UFP Technologies (NASDAQ:UFPT) Issues Earnings Results - MarketBeat — MarketBeat neutral
Generated 2026-07-26T08:02:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop ten customers69%10-K Item 1A: 'Our top ten customers represented approximately 68.8%, 68.1%, and 59.3% of our total net sales in 2025, 2024, and 2023, respectively.'
- LOWCustomerIntuitive Surgical SARL24%10-K Item 1A: 'Two customers (Intuitive Surgical SARL and Stryker) comprised approximately 24.3% and 21.5%, respectively, of our net sales for the year ended December 31, 2025'
- LOWCustomerStryker22%10-K Item 1A: 'Two customers (Intuitive Surgical SARL and Stryker) comprised approximately 24.3% and 21.5%, respectively, of our net sales for the year ended December 31, 2025'
- MEDIUMSuppliercross-linked and technical polyurethane foam and TPU suppliers10-K Item 1: 'the Company relies upon a limited number of suppliers for cross-linked and technical polyurethane foams, and TPU'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02MEDIUMThe company appointed Ryan Stafford as General Counsel, SVP of Human Resources, and Secretary effective June 4, 2026, succeeding Christopher P. Litterio, who previously disclosed plans to retire after a transition period.SEC filing →
- 2026-05-26Item 5.02MEDIUMGeneral Counsel, Secretary, and SVP of Human Resources Christopher P. Litterio informed the company on May 19, 2026 that he plans to retire after a period of transition. No successor named in this filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $237.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: top ten customers (68.8%); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $221.63. Score 5.2/10, moderate confidence.
Take-profit target: $275.82 (+16.3% upside). Prior stop was $221.63. Stop-loss: $221.63.
Concentration risk — Customer: top ten customers (68.8%); Weak growth; Negative momentum.
UFP Technologies, Inc. trades at a P/E of 26.9 (forward 20.3). TrendMatrix value score: 5.7/10. Verdict: Sell.
10 analysts cover UFPT with a consensus score of 3.9/5. Average price target: $325.
What does UFP Technologies, Inc. do?UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient...
UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient medical devices and components for minimally invasive surgery, infection prevention, wound care, and orthopedics. The company generates revenue by manufacturing custom-engineered products for medical device makers; its top ten customers represented approximately 68.8% of net sales in 2025, including Intuitive Surgical SARL and Stryker at 24.3% and 21.5%, respectively.